PUBLIC COMPANY
saveROCHE
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
Where ROCHE is staffing up — a leading indicator of pipeline and commercial priorities.
News
- As part of sales reorganization, Novo will cut 215 employees at US HQFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 9h ago
- STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and moreSanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:stat · 10h ago
- ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loomAs the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.fiercebiotech · 17h ago
- STAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in ChinaBig drugmakers tell U.S. House committee they will halt clinical trials at some hospitals in China.stat · 1d ago
- STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and moreMerck is entering a research collaboration with Isomorphic Labs, the AI drug designer built on a Nobel-winning technologystat · 1d ago
- Teva loses R&D head Eric Hughes amid push to grow innovative medicines businessTeva’s R&D chief Eric Hughes, M.D., Ph.D., has resigned one week after the company showcased its push to grow its innovative medicines business.fiercebiotech · 1d ago
- STAT+: NIH to move last group of its research chimps to a sanctuaryThe last chimpanzees owned by the U.S. government and still living in a laboratory will be moved to a sanctuary next year.stat · 2d ago
- CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’sBiogen and AriBio reported wins for their respective therapies targeting Alzheimer’s disease, while Priavoid and Cognito Therapeutics missed the mark—though the latter plans to file for FDA approva…biospace · 2d ago
- STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and moreThe Trump administration is pulling the nomination of Heidi Overton to lead the FDA over concerns she lacked support to get confirmed by the Senatestat · 2d ago
- FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSKThe FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.biopharma_dive · 2d ago
comments(0)
5-min edit window · permanent after that